These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8710920)

  • 1. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
    Liu C; Tadayoni BM; Bourret LA; Mattocks KM; Derr SM; Widdison WC; Kedersha NL; Ariniello PD; Goldmacher VS; Lambert JM; Blättler WA; Chari RV
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8618-23. PubMed ID: 8710920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology evaluation: C242-DM1, ImmunoGen Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
    Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
    Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice.
    Debinski W; Karlsson B; Lindholm L; Siegall CB; Willingham MC; FitzGerald D; Pastan I
    J Clin Invest; 1992 Aug; 90(2):405-11. PubMed ID: 1644913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
    Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
    Henry MD; Wen S; Silva MD; Chandra S; Milton M; Worland PJ
    Cancer Res; 2004 Nov; 64(21):7995-8001. PubMed ID: 15520207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semisynthetic maytansine analogues for the targeted treatment of cancer.
    Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
    J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
    Chari RV; Martell BA; Gross JL; Cook SB; Shah SA; Blättler WA; McKenzie SJ; Goldmacher VS
    Cancer Res; 1992 Jan; 52(1):127-31. PubMed ID: 1727373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-DM1 conjugates as cancer therapeutics.
    Lopus M
    Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
    Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
    Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.